 LEXINGTON, Mass., Feb. 03, 2021 GLOBE NEWSWIRE -- Kaleido Biosciences, Inc. Nasdaq: KLDO, a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a public offering price of 11.50 per share. In addition, Kaleido has granted the underwriters a 30-day option to purchase up to an additional 787,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Kaleido from this offering are expected to be approximately 60.4 million, before deducting underwriting discounts and commissions and other estimated offering expenses and excluding any exercise of the underwriters option to purchase additional shares. All of the shares are being offered by Kaleido. The offering is expected to close on February 8, 2021, subject to customary closing conditions. 